Unity Biotechnology (Unity Biotechnology) Change In Inventory : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Unity Biotechnology Change In Inventory?

Unity Biotechnology's change in inventory for the quarter that ended in Mar. 2024 was $0.00 Mil. It means Unity Biotechnology's inventory stayed the same from Dec. 2023 to Mar. 2024 .

Unity Biotechnology's change in inventory for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Unity Biotechnology's inventory stayed the same from Dec. 2022 to Dec. 2023 .

Unity Biotechnology's Total Inventories for the quarter that ended in Mar. 2024 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Unity Biotechnology Change In Inventory Historical Data

The historical data trend for Unity Biotechnology's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Unity Biotechnology Change In Inventory Chart

Unity Biotechnology Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Inventory

Get a 7-Day Free Trial

Unity Biotechnology Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Inventory	Get a 7-Day Free Trial															-	-	-	-	-

Unity Biotechnology Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Unity Biotechnology (NAS:UBX) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Unity Biotechnology's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Unity Biotechnology's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Unity Biotechnology's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=	N/A

Unity Biotechnology Change In Inventory Related Terms

Thank you for viewing the detailed overview of Unity Biotechnology's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Unity Biotechnology (Unity Biotechnology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Unity Biotechnology Inc (NAS:UBX) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

9U90:Germany 9U90:Germany

Address

285 East Grand Avenue, South San Francisco, CA, USA, 94080

Website

https://www.unitybiotechnology.com

Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases.

Executives

Anirvan Ghosh	director, officer: Chief Executive Officer	C/O UNITY BIOTECHNOLOGY, INC., 285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Jamie Dananberg	officer: Chief Medical Officer	3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Michael P. Samar	director	C/O ASSEMBLY BIOSCIENCES, INC., 11711 N. MERIDIAN ST. SUITE 310, CARMEL IN 46032
Alexander Hieu Nguyen	officer: See Remarks	C/O UNITY BIOTECHNOLOGY, INC., 285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Nathaniel E David	director, officer: President	C/O KYTHERA BIOPHARMACEUTICALS, INC., 27200 WEST AGOURA ROAD, SUITE 200, CALABASAS CA 91301
Gilmore Neil O'neill	director	215 FIRST STREET, CAMBRIDGE MA 02142
Alexander Azoy	officer: See Remarks	30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Lynne Marie Sullivan	officer: See Remarks	C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Robert Nelsen	director	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Graham K Cooper	director	C/O RECEPTOS, INC., 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Paul L Berns	director	11080 CIRCLEPOINT RD., STE, 200, WESTMINSTER CO 80020
Camille D Samuels	director	2463 JACKSON ST., SAN FRANCISCO CA 94115
Kristina Burow	director	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
David L. Lacey	director	3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Dan Marquess	officer: Chief Scientific Officer	3280 BAYSHORE BOULEVARD, BRISBANE CA 94005